Logo image of HZNP

HORIZON THERAPEUTICS PLC (HZNP) Stock Fundamental Analysis

NASDAQ:HZNP - Nasdaq - IE00BQPVQZ61 - Common Stock - Currency: USD

116.3  +0.05 (+0.04%)

After market: 116.34 +0.04 (+0.03%)

Fundamental Rating

6

Overall HZNP gets a fundamental rating of 6 out of 10. We evaluated HZNP against 560 industry peers in the Biotechnology industry. HZNP has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. HZNP has a decent growth rate and is not valued too expensively. These ratings would make HZNP suitable for quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

HZNP had positive earnings in the past year.
HZNP had a positive operating cash flow in the past year.
HZNP had positive earnings in 4 of the past 5 years.
In the past 5 years HZNP always reported a positive cash flow from operatings.
HZNP Yearly Net Income VS EBIT VS OCF VS FCFHZNP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 500M 1B

1.2 Ratios

With an excellent Return On Assets value of 4.71%, HZNP belongs to the best of the industry, outperforming 95.21% of the companies in the same industry.
HZNP has a Return On Equity of 8.25%. This is amongst the best in the industry. HZNP outperforms 95.38% of its industry peers.
With an excellent Return On Invested Capital value of 5.35%, HZNP belongs to the best of the industry, outperforming 95.87% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for HZNP is significantly below the industry average of 15.80%.
Industry RankSector Rank
ROA 4.71%
ROE 8.25%
ROIC 5.35%
ROA(3y)6.1%
ROA(5y)6.05%
ROE(3y)10.47%
ROE(5y)10.88%
ROIC(3y)6.68%
ROIC(5y)4.8%
HZNP Yearly ROA, ROE, ROICHZNP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 20 -20

1.3 Margins

The Profit Margin of HZNP (12.02%) is better than 96.04% of its industry peers.
In the last couple of years the Profit Margin of HZNP has declined.
HZNP has a better Operating Margin (15.58%) than 96.53% of its industry peers.
In the last couple of years the Operating Margin of HZNP has grown nicely.
Looking at the Gross Margin, with a value of 75.21%, HZNP belongs to the top of the industry, outperforming 84.49% of the companies in the same industry.
HZNP's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 15.58%
PM (TTM) 12.02%
GM 75.21%
OM growth 3Y23.86%
OM growth 5YN/A
PM growth 3Y-31.18%
PM growth 5YN/A
GM growth 3Y1.14%
GM growth 5Y6.97%
HZNP Yearly Profit, Operating, Gross MarginsHZNP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 20 -20 40 60

More info and screens

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), HZNP is destroying value.
HZNP has about the same amout of shares outstanding than it did 1 year ago.
HZNP has a better debt/assets ratio than last year.
HZNP Yearly Shares OutstandingHZNP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M
HZNP Yearly Total Debt VS Total AssetsHZNP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2B 4B 6B 8B

2.2 Solvency

An Altman-Z score of 5.10 indicates that HZNP is not in any danger for bankruptcy at the moment.
HZNP's Altman-Z score of 5.10 is amongst the best of the industry. HZNP outperforms 81.35% of its industry peers.
The Debt to FCF ratio of HZNP is 2.67, which is a good value as it means it would take HZNP, 2.67 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of HZNP (2.67) is better than 95.54% of its industry peers.
HZNP has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.48, HZNP is not doing good in the industry: 74.92% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 2.67
Altman-Z 5.1
ROIC/WACC0.75
WACC7.16%
HZNP Yearly LT Debt VS Equity VS FCFHZNP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 1B 2B 3B 4B 5B

2.3 Liquidity

A Current Ratio of 4.27 indicates that HZNP has no problem at all paying its short term obligations.
With a Current ratio value of 4.27, HZNP perfoms like the industry average, outperforming 41.58% of the companies in the same industry.
HZNP has a Quick Ratio of 4.09. This indicates that HZNP is financially healthy and has no problem in meeting its short term obligations.
HZNP has a Quick ratio of 4.09. This is comparable to the rest of the industry: HZNP outperforms 40.92% of its industry peers.
Industry RankSector Rank
Current Ratio 4.27
Quick Ratio 4.09
HZNP Yearly Current Assets VS Current LiabilitesHZNP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 1B 2B 3B

More info and screens

6

3. Growth

3.1 Past

HZNP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.39%.
The Earnings Per Share has been growing by 33.01% on average over the past years. This is a very strong growth
The Revenue has decreased by -4.42% in the past year.
The Revenue has been growing by 28.00% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-19.39%
EPS 3Y34.76%
EPS 5Y33.01%
EPS Q2Q%12.15%
Revenue 1Y (TTM)-4.42%
Revenue growth 3Y40.8%
Revenue growth 5Y28%
Sales Q2Q%7.82%

3.2 Future

The Earnings Per Share is expected to grow by 15.92% on average over the next years. This is quite good.
Based on estimates for the next years, HZNP will show a quite strong growth in Revenue. The Revenue will grow by 9.94% on average per year.
EPS Next Y-5.01%
EPS Next 2Y8.89%
EPS Next 3Y11.9%
EPS Next 5Y15.92%
Revenue Next Year5.55%
Revenue Next 2Y9.53%
Revenue Next 3Y10.34%
Revenue Next 5Y9.94%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
HZNP Yearly Revenue VS EstimatesHZNP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2B 4B 6B
HZNP Yearly EPS VS EstimatesHZNP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 10

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 25.90, the valuation of HZNP can be described as expensive.
HZNP's Price/Earnings ratio is rather cheap when compared to the industry. HZNP is cheaper than 95.54% of the companies in the same industry.
When comparing the Price/Earnings ratio of HZNP to the average of the S&P500 Index (26.17), we can say HZNP is valued inline with the index average.
A Price/Forward Earnings ratio of 20.14 indicates a rather expensive valuation of HZNP.
Compared to the rest of the industry, the Price/Forward Earnings ratio of HZNP indicates a rather cheap valuation: HZNP is cheaper than 96.53% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.10, HZNP is valued at the same level.
Industry RankSector Rank
PE 25.9
Fwd PE 20.14
HZNP Price Earnings VS Forward Price EarningsHZNP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

94.88% of the companies in the same industry are more expensive than HZNP, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, HZNP is valued cheaply inside the industry as 96.37% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 27.79
EV/EBITDA 27.94
HZNP Per share dataHZNP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

The excellent profitability rating of HZNP may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.78
EPS Next 2Y8.89%
EPS Next 3Y11.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HZNP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HORIZON THERAPEUTICS PLC

NASDAQ:HZNP (10/5/2023, 8:25:26 PM)

After market: 116.34 +0.04 (+0.03%)

116.3

+0.05 (+0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2023-08-08/bmo
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins Owners0.58%
Ins Owner Change0%
Market Cap26.63B
Analysts50.91
Price Target118.83 (2.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.7%
Min EPS beat(2)-27.35%
Max EPS beat(2)13.95%
EPS beat(4)3
Avg EPS beat(4)4.23%
Min EPS beat(4)-27.35%
Max EPS beat(4)21.5%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.41%
Min Revenue beat(2)-9.59%
Max Revenue beat(2)6.77%
Revenue beat(4)3
Avg Revenue beat(4)-0.15%
Min Revenue beat(4)-9.59%
Max Revenue beat(4)6.77%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.76%
EPS NY rev (1m)0%
EPS NY rev (3m)-17.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.27%
Valuation
Industry RankSector Rank
PE 25.9
Fwd PE 20.14
P/S 7.31
P/FCF 27.79
P/OCF 25.59
P/B 5.01
P/tB 26.53
EV/EBITDA 27.94
EPS(TTM)4.49
EY3.86%
EPS(NY)5.77
Fwd EY4.97%
FCF(TTM)4.19
FCFY3.6%
OCF(TTM)4.54
OCFY3.91%
SpS15.92
BVpS23.19
TBVpS4.38
PEG (NY)N/A
PEG (5Y)0.78
Profitability
Industry RankSector Rank
ROA 4.71%
ROE 8.25%
ROCE 6.77%
ROIC 5.35%
ROICexc 7.58%
ROICexgc 27.86%
OM 15.58%
PM (TTM) 12.02%
GM 75.21%
FCFM 26.3%
ROA(3y)6.1%
ROA(5y)6.05%
ROE(3y)10.47%
ROE(5y)10.88%
ROIC(3y)6.68%
ROIC(5y)4.8%
ROICexc(3y)9.75%
ROICexc(5y)6.96%
ROICexgc(3y)39.54%
ROICexgc(5y)N/A
ROCE(3y)8.46%
ROCE(5y)6.07%
ROICexcg growth 3Y27.62%
ROICexcg growth 5YN/A
ROICexc growth 3Y33.99%
ROICexc growth 5YN/A
OM growth 3Y23.86%
OM growth 5YN/A
PM growth 3Y-31.18%
PM growth 5YN/A
GM growth 3Y1.14%
GM growth 5Y6.97%
F-Score6
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 2.67
Debt/EBITDA 2.66
Cap/Depr 21.15%
Cap/Sales 2.26%
Interest Coverage 4.07
Cash Conversion 108.78%
Profit Quality 218.81%
Current Ratio 4.27
Quick Ratio 4.09
Altman-Z 5.1
F-Score6
WACC7.16%
ROIC/WACC0.75
Cap/Depr(3y)32.95%
Cap/Depr(5y)21.63%
Cap/Sales(3y)3.95%
Cap/Sales(5y)2.73%
Profit Quality(3y)169.09%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.39%
EPS 3Y34.76%
EPS 5Y33.01%
EPS Q2Q%12.15%
EPS Next Y-5.01%
EPS Next 2Y8.89%
EPS Next 3Y11.9%
EPS Next 5Y15.92%
Revenue 1Y (TTM)-4.42%
Revenue growth 3Y40.8%
Revenue growth 5Y28%
Sales Q2Q%7.82%
Revenue Next Year5.55%
Revenue Next 2Y9.53%
Revenue Next 3Y10.34%
Revenue Next 5Y9.94%
EBIT growth 1Y-37.19%
EBIT growth 3Y74.4%
EBIT growth 5YN/A
EBIT Next Year6.03%
EBIT Next 3Y14.62%
EBIT Next 5Y17.3%
FCF growth 1Y83.52%
FCF growth 3Y42.98%
FCF growth 5Y33.65%
OCF growth 1Y72.19%
OCF growth 3Y43.43%
OCF growth 5Y34.64%